Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8 + T cells in the tumor microenvironment

ConclusionsThis study suggests that the frequency of eTreg cells in TILs could be a biomarker for stratifying clinical responses to RAM-containing therapies. Further, we propose that RAM may be employed as an immuno-modulator in combination with immune checkpoint blockade. (Source: Journal for Immunotherapy of Cancer)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2ORC8QN